active-semi® Releases First New High-Performance Integrated Intelligent BLDC Motor Controller and Driver with 150MHz Arm® Cortex®-M4F MCU
active-semi®, Inc. (www.active-semi.com) announced today the first member of a new family of PAC® high-performance motor controllers with the PAC5523 IC. It is supported by an Evaluation Kit (EVK) and accompanying firmware for easy and fast evaluation of advanced motor control solutions.
The new PAC5523 contains the highest-performance MCU found in an integrated motor control and driver product on the market. It contains a 150MHz Arm® Cortex®-M4F MCU with 128kB FLASH, 32kB SRAM and an integrated Floating Point Unit (FPU) with Digital Signal Processor (DSP) instructions for highly efficient implementation of motor control and drive applications. The MCU also contains 4-level code protection, a cache for high-speed FLASH access, ECC for SRAM data and a CRC engine.
The PAC5523 also integrates highly-optimized peripherals specifically designed for BLDC motor control applications.
The 70V PAC5523 is optimized for battery-powered and other BLDC applications up to 48V. Integrated with the high-performance MCU is the power management, gate drivers and signal-conditioning for 3-phase inverter applications. The PAC5523 may be directly supplied with a battery of up to 20 or higher voltages using the 70V DC/DC Buck or SEPIC controller Multi-Mode Power ManagerTM (MMPM). The PAC5523 implements a Total Hibernate ModeTM which manages battery life and system efficiency by reducing quiescent current to 18uA.
The Application-Specific Power DriversTM (ASPD) integrates 70V/1.5A gate drivers for high power applications with 2-level dead-time protection for the external MOSFET-based inverter. The Configurable Analog Front-EndTM (CAFE) contains 3 Differential Programmable Gain Amplifiers (PGAs), 4 single-ended PGAs, 10 comparators, buffers and DACs that can be used for signal sampling and filtering for the control applications, minimizing the need for external components.
“The PAC5523 contains both a high-performance and high-memory MCU with integrated 70V DC/DC Controller and Gate Drivers, configurable analog front-end, coupled with active-semi®’s Total Hibernate Mode™ and other patented features, delivers the highest-performing and smallest system design at the highest system efficiency,” says David Briggs, Vice-President and General Manager at active-semi®. “We are excited about the rapidly expanding customer base that is now ramping into production with PAC5523.”
In a small 6mm x 6mm QFN package with all of the integration, the PAC5523 can realize an extremely small BOM and physical design size for compact BLDC battery-powered applications.
The PAC5523EVK extends the PAC® family of evaluation kits (EVKs) enabling fast prototyping for various applications including power tools, garden tools, telecom fans, battery-powered vehicles, drones, radio controlled cars, and general-purpose BLDC applications. Along with active-semi®’s motor control firmware and IP library, the PAC5523 will simplify system development with sensored and sensorless FOC and sensorless trapezoidal motor control applications for high-voltage battery powered applications.
PAC5523 IC and PAC5523EVK1 are available from leading distributors.
For more information on active-semi® and Intelligent Motor Control solutions, visit https://active-semi.com/products/intelligent-motor-control.
About active-semi ®
Founded in 2004 in Silicon Valley and headquartered in Dallas, Texas, active-semi® is a rapidly emerging leader in multi-billion-dollar power management and intelligent digital motor drive IC markets. The company’s portfolio of analog and mixed signal SoCs provide scalable core platforms used in charging, powering and embedded digital control systems for industrial, commercial and consumer applications. active-semi® offers Power Application Controllers® (PAC®), DC-DC and ActivePMU™ products that significantly reduce solution size and cost, improve system reliability, and shorten system development cycle-time.
active-semi® is a multi-national company with over 170 patents granted and pending. active-semi® International Inc. is a Cayman Island corporation backed by leading Venture Capital firms, including USVP, Tenaya Capital, LG and LDV Partners.
More information at www.active-semi.com
Bernd Krafthoefer, +1-214-453-1422
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i